MicroRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway

FEBS Journal

Volumn 280, Issue 16, 2013, Pages 3962-3974

  Cui, Wenjing ^a   Zhang, Shuai ^b   Shan, Changliang ^b   Zhou, Li ^a   Zhou, Zhemin ^a  

^a JIANGNAN UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; cell cycle; cell proliferation; epidermal growth factor receptor; microRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 133A; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; MIRN133 MICRORNA, HUMAN; RECOMBINANT PROTEIN; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; EGFR GENE; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; CELL CYCLE; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; DRUG ANTAGONISM; FEMALE; GENETICS; MAMMARY GLAND; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; REPORTER GENE; TUMOR CELL LINE;

BREAST CANCER; CELL CYCLE; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA;

3' UNTRANSLATED REGIONS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENES, REPORTER; HUMANS; MAMMARY GLANDS, HUMAN; MICRORNAS; MUTATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84885933561     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12398     Document Type: Article

References (51)

1. Zhao Y, Samal E, &, Srivastava D, (2005) Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214-220.
2. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, &, Croce CM, (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice. Proc Natl Acad Sci USA 103, 7024-7029.
3. Tay Y, Zhang J, &, Thomson AM, (2009) Lim B & Rigoutsos I (2008) MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455, 1124-1128. Corrigendium. Nature 458, 538.
4. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, De Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, et al,. (2008) E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13, 272-286.
5. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, &, Zhuang SM, (2009) MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 69, 1135-1142.
6. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, &, Zhuang SM, (2010) Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51, 836-845.
7. Croce CM, (2008) Oncogenes and cancer. N Engl J Med 358, 502-511.
8. Esquela-Kerscher A, &, Slack FJ, (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6, 259-269.
9. He L, He X, Lowe SW, &, Hannon GJ, (2007) microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 7, 819-822.
10. De Vito C, Riggi N, Suva ML, Janiszewska M, Horlbeck J, Baumer K, Provero P, &, Stamenkovic I, (2011) Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. PLoS ONE 6, e23592.
11. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, &, Safe S, (2010) MicroRNA-27a indirectly regulates estrogen receptor α expression and hormone responsiveness in MCF-7 breast cancer cells. Endocrinology 151, 2462-2473.
12. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, &, Richer JK, (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8, 1055-1066.
13. Pan YZ, Morris ME, &, Yu AM, (2009) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75, 1374-1379.
14. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, &, Weiss GJ, (2011) miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 6, 482-488.
15. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al,. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18, 997-1006.
16. Taylor DD, &, Gercel-Taylor C, (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110, 13-21.
17. Hu X, Schwarz JK, Lewis JS Jr, Huettner PC, Rader JS, Deasy JO, Grigsby PW, &, Wang X, (2010) A microRNA expression signature for cervical cancer prognosis. Cancer Res 70, 1441-1448.
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, &, Forman D, (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90.
19. Bendre M, Gaddy D, Nicholas RW, &, Suva LJ, (2003) Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res 415, S39-S45.
20. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, &, Weinberg RA, (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137, 1032-1046.
21. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, &, Massague J, (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152.
22. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T, et al,. (2008) A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 182, 509-517.
23. Cui W, Zhang Y, Hu N, Shan C, Zhang S, Zhang W, Zhang X, &, Ye L, (2010) miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3′ UTR of CD46. Cancer Biol Ther 10, 232-241.
24. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Menard S, Croce CM, &, Tagliabue E, (2009) microRNA-205 regulates HER3 in human breast cancer. Cancer Res 69, 2195-2200.
25. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, &, Lund AH, (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283, 1026-1033.
26. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, &, Tuschl T, (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12, 735-739.
27. Li Z, Hassan MQ, Volinia S, Van Wijnen AJ, Stein JL, Croce CM, Lian JB, &, Stein GS, (2008) A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci USA 105, 13906-13911.
28. Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, &, Nana-Sinkam SP, (2009) MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 388, 483-489.
29. Herbst RS, (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59, 21-26.
30. Downward J, Parker P, &, Waterfield MD, (1984) Autophosphorylation sites on the epidermal growth factor receptor. Nature 311, 483-485.
31. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9, 550-562.
32. Skomedal H, Kristensen GB, Lie AK, &, Holm R, (1999) Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 73, 223-228.
33. Yoon MK, Mitrea DM, Ou L, &, Kriwacki RW, (2012) Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40, 981-988.
34. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, &, Thun M, (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56, 168-183.
35. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, &, Nakagawa M, (2010) miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102, 883-891.
36. Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, Yoshida S, Suzuki M, Yoshino I, &, Seki N, (2012) Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 57, 38-45.
37. Wu ZS, Wang CQ, Xiang R, Liu X, Ye S, Yang XQ, Zhang GH, Xu XC, Zhu T, &, Wu Q, (2012) Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 12, 51.
38. Kinoshita T, Nohata N, Fuse M, Hanazawa T, Kikkawa N, Fujimura L, Watanabe-Takano H, Yamada Y, Yoshino H, Enokida H, et al,. (2012) Tumor suppressive microRNA-133a regulates novel targets: moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 418, 378-383.
39. Ruebel K, Leontovich AA, Stilling GA, Zhang S, Righi A, Jin L, &, Lloyd RV, (2010) MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 23, 367-375.
40. Kinoshita T, Nohata N, Watanabe-Takano H, Yoshino H, Hidaka H, Fujimura L, Fuse M, Yamasaki T, Enokida H, Nakagawa M, et al,. (2012) Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma. Int J Oncol 40, 1770-1778.
41. Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N, &, Nakagawa M, (2012) Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol 40, 1821-1830.
42. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, &, Greene MI, (2007) ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 117, 2051-2058.
43. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, &, Hung MC, (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393.
44. Gan Y, Shi C, Inge L, Hibner M, Balducci J, &, Huang Y, (2010) Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29, 4947-4958.
45. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, et al,. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68, 3566-3572.
46. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, et al,. (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 106, 12085-12090.
47. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Tanaka Y, Chiyomaru T, et al,. (2012) miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res 19, 73-84.
48. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zanker KS, Brandt BH, &, Dittmar T, (2012) The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. J Pathol 227, 234-244.
49. Bowen T, Jenkins RH, &, Fraser DJ, (2013) MicroRNAs, transforming growth factor β-1, and tissue fibrosis. J Pathol 229, 274-285.
50. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, et al,. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361, 1437-1447.
51. Barco R, Hunt LB, Frump AL, Garcia CB, Benesh A, Caldwell RL, &, Eid JE, (2007) The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Mol Biol Cell 18, 4003-4012.